{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:56:40Z","timestamp":1780318600136,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.bcp.2020.113911","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T22:32:17Z","timestamp":1584052337000},"page":"113911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Targeting replication stress response using polypurine reverse hoogsteen hairpins directed against WEE1 and CHK1 genes in human cancer cells"],"prefix":"10.1016","volume":"175","author":[{"given":"Eva","family":"Aubets","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"No\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos J.","family":"Ciudad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.113911_b0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2020.113911_b0010","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/nar\/gkr697","article-title":"Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication","volume":"40","author":"S\u00f8rensen","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2020.113911_b0015","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.4161\/cc.26062","article-title":"Wee1 kinase as a target for cancer therapy","volume":"12","author":"Do","year":"2013","journal-title":"Cell Cycle."},{"key":"10.1016\/j.bcp.2020.113911_b0020","doi-asserted-by":"crossref","first-page":"153634","DOI":"10.1155\/2013\/153634","article-title":"RNA splicing: a new player in the DNA damage response","volume":"2013","author":"Lenzken","year":"2013","journal-title":"Int. J. Cell Biol."},{"key":"10.1016\/j.bcp.2020.113911_b0025","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell."},{"key":"10.1016\/j.bcp.2020.113911_b0030","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Mar\u00e9chal","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bcp.2020.113911_b0035","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Kastan","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2020.113911_b0040","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","article-title":"Targeting WEE1 Kinase in Cancer","volume":"37","author":"Matheson","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2020.113911_b0045","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nrd4553","article-title":"Exploiting replicative stress to treat cancer","volume":"14","author":"Dobbelstein","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2020.113911_b0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1073\/pnas.1104767109","article-title":"Checkpoint kinase 1 (Chk1)-short is a splice variant and endogenous inhibitor of Chk1 that regulates cell cycle and DNA damage checkpoints","volume":"109","author":"Pabla","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bcp.2020.113911_b0055","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1007\/s00018-013-1307-3","article-title":"Checkpoint kinase 1 in DNA damage response and cell cycle regulation","volume":"70","author":"Patil","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcp.2020.113911_b0060","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12885-017-3131-x","article-title":"A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients","volume":"17","author":"Laquente","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2020.113911_b0065","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10637-016-0368-1","article-title":"PHASE II STUDIES Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer","volume":"34","author":"Scagliotti","year":"2016","journal-title":"Invest. New Drugs."},{"key":"10.1016\/j.bcp.2020.113911_b0070","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.lungcan.2014.06.008","article-title":"Randomized phase II trial of pemetrexed\/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma","volume":"85","author":"Krug","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2020.113911_b0075","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00280-013-2234-6","article-title":"Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours","volume":"72","author":"Seto","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113911_b0080","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00280-014-2380-5","article-title":"Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors","volume":"73","author":"Sausville","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113911_b0085","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.00730","article-title":"Dose escalation trial of the Wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients With locally advanced pancreatic cancer","author":"Cuneo","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113911_b0090","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","article-title":"Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors","volume":"34","author":"Leijen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113911_b0095","doi-asserted-by":"crossref","unstructured":"J. V Forment, M.J. O\u2019connor, Targeting the replication stress response in cancer, (2018). doi: 10.1016\/j.pharmthera.2018.03.005.","DOI":"10.1016\/j.pharmthera.2018.03.005"},{"key":"10.1016\/j.bcp.2020.113911_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers9050041","article-title":"Targeting the ATR-CHK1 axis in cancer therapy","volume":"9","author":"Rundle","year":"2017","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.bcp.2020.113911_b0105","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.bcp.2020.113911_b0110","unstructured":"Home - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ (accessed September 5, 2019)."},{"key":"10.1016\/j.bcp.2020.113911_b0115","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/hum.2010.102","article-title":"Coding polypurine hairpins cause target-induced cell death in breast cancer cells","volume":"22","author":"de Almagro","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bcp.2020.113911_b0120","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/nat.2015.0531","article-title":"Effect of polypurine reverse hoogsteen hairpins on relevant cancer target genes in different human cell lines","volume":"25","author":"Villalobos","year":"2015","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.bcp.2020.113911_b0125","doi-asserted-by":"crossref","first-page":"11579","DOI":"10.1074\/jbc.M900981200","article-title":"Polypurine hairpins directed against the template strand of DNA knock down the expression of mammalian genes","volume":"284","author":"de Almagro","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.113911_b0130","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.bcp.2013.09.013","article-title":"Polypurine reverse Hoogsteen hairpins as a gene therapy tool against survivin in human prostate cancer PC3 cells in vitro and in vivo","volume":"86","author":"Rodr\u00edguez","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113911_b0135","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/oli.2005.15.269","article-title":"Strand displacement of double-stranded DNA by triplex-forming antiparallel purine-hairpins","volume":"15","author":"Coma","year":"2005","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.bcp.2020.113911_b0140","doi-asserted-by":"crossref","DOI":"10.2174\/0929867324666170301114127","article-title":"Polypurine reverse Hoogsteen hairpins as a gene silencing tool for cancer","volume":"24","author":"Ciudad","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2020.113911_b0145","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-Fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer."},{"key":"10.1016\/j.bcp.2020.113911_b0150","first-page":"293","article-title":"Cancer chemotherapy: targeting folic acid synthesis","volume":"2","author":"Hagner","year":"2010","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bcp.2020.113911_b0155","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the chou-talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2020.113911_b0160","doi-asserted-by":"crossref","unstructured":"X. Jiang, W. Li, X. Li, H. Bai, Z. Zhang, Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer, (2019). doi: 10.2147\/CMAR.S200524.","DOI":"10.2147\/CMAR.S200524"},{"key":"10.1016\/j.bcp.2020.113911_b0165","unstructured":"U.S. Food and Drug Administration. https:\/\/www.fda.gov\/ (accessed September 1, 2019)."},{"key":"10.1016\/j.bcp.2020.113911_b0170","unstructured":"European Medicines Agency. https:\/\/www.ema.europa.eu\/en (accessed December 20, 2019)."},{"key":"10.1016\/j.bcp.2020.113911_b0175","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1021\/mp400431f","article-title":"Stability and immunogenicity properties of the gene-silencing polypurine reverse Hoogsteen hairpins","volume":"11","author":"Villalobos","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2020.113911_b0180","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3390\/biom5031912","article-title":"Targeting the checkpoint to kill cancer cells","volume":"5","author":"Benada","year":"2015","journal-title":"Biomolecules."},{"key":"10.1016\/j.bcp.2020.113911_b0185","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","article-title":"DNA replication stress as a hallmark of cancer","volume":"10","author":"Macheret","year":"2015","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.bcp.2020.113911_b0190","doi-asserted-by":"crossref","DOI":"10.1038\/s41389-019-0147-x","article-title":"Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death","volume":"8","author":"van Harten","year":"2019","journal-title":"Oncogenesis"},{"key":"10.1016\/j.bcp.2020.113911_b0195","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1128\/MCB.00412-12","article-title":"Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption","volume":"32","author":"Beck","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bcp.2020.113911_b0200","doi-asserted-by":"crossref","first-page":"10546","DOI":"10.18632\/oncotarget.2508","article-title":"Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis","volume":"5","author":"Mak","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2020.113911_b0205","doi-asserted-by":"crossref","first-page":"73705","DOI":"10.18632\/oncotarget.17848","article-title":"Prolonged mitotic arrest induced by Wee1 inhibition sensitizes breast cancer cells to paclitaxel","volume":"8","author":"Lewis","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2020.113911_b0210","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s10495-014-1010-3","article-title":"The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells","volume":"19","author":"Wang","year":"2014","journal-title":"Apoptosis"},{"key":"10.1016\/j.bcp.2020.113911_b0215","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.cellsig.2015.01.020","article-title":"Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells","volume":"27","author":"Vera","year":"2015","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bcp.2020.113911_b0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100495","article-title":"Efficient induction of apoptosis by wee1 kinase inhibition in hepatocellular carcinoma cells","volume":"9","author":"Kogiso","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2020.113911_b0225","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.108","article-title":"Mitotic catastrophe and cell death induced by depletion of centrosomal proteins","volume":"4","author":"Kimura","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2020.113911_b0230","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/sj.onc.1207528","article-title":"Cell death by mitotic catastrophe: a molecular definition","volume":"23","author":"Castedo","year":"2004","journal-title":"Oncogene."},{"key":"10.1016\/j.bcp.2020.113911_b0235","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1038\/onc.2012.296","article-title":"Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination","volume":"32","author":"Krajewska","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2020.113911_b0240","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1158\/1535-7163.MCT-16-0660","article-title":"A small-molecule inhibitor of WEE1, AZD1775, synergizes with olaparib by impairing homologous recombination and enhancing DNA damage and apoptosis in acute leukemia","volume":"16","author":"Garcia","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2020.113911_b0245","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-12-3748","article-title":"Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776","volume":"19","author":"Engelke","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2020.113911_b0250","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1158\/1535-7163.MCT-11-0469","article-title":"Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines","volume":"10","author":"Sarcar","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2020.113911_b0255","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/sj.neo.7900175","article-title":"Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism","volume":"3","author":"Luo","year":"2001","journal-title":"Neoplasia"},{"key":"10.1016\/j.bcp.2020.113911_b0260","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/0008-5472.CAN-12-2669","article-title":"Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma","volume":"73","author":"Russell","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2020.113911_b0265","doi-asserted-by":"crossref","first-page":"11964","DOI":"10.1073\/pnas.0604987103","article-title":"Checkpoint kinase 1 (Chk1) is required for mitotic progression through negative regulation of polo-like kinase 1 (Plk1)","volume":"103","author":"Tang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220301398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220301398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:16:19Z","timestamp":1757769379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220301398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":53,"alternative-id":["S0006295220301398"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.113911","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting replication stress response using polypurine reverse hoogsteen hairpins directed against WEE1 and CHK1 genes in human cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.113911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113911"}}